Lumos Labs, makers of Lumosity, settles with FTC over allegations of deceptive advertisement

Lumos Labs

lumosity big

 

The creators and marketers of the Lumosity “brain training” program have agreed to settle Federal Trade Commission charges alleging that they deceived consumers with unfounded claims that Lumosity games can help users perform better at work and in school, and reduce or delay cognitive impairment associated with age and other serious health conditions.

As part of the settlement, Lumos Labs, the company behind Lumosity, will pay $2 million in redress and will notify subscribers of the FTC action and provide them with an easy way to cancel their auto-renewal to avoid future billing.

According to the FTC’s complaint, the Lumosity program consists of 40 games purportedly designed to target and train specific areas of the brain. The company advertised that training on these games for 10 to 15 minutes three or four times a week could help users achieve their “full potential in every aspect of life.” The company sold both online and mobile app subscriptions, with options ranging from monthly ($14.95) to lifetime ($299.95) memberships.

Lumosity has been widely promoted though TV and radio advertisements on networks including CNN, Fox News, the History Channel, National Public Radio, Pandora, Sirius XM, and Spotify. The defendants also marketed through emails, blog posts, social media, and on their website, Lumosity.com, and used Google AdWords to drive traffic to their website, purchasing hundreds of keywords related to memory, cognition, dementia, and Alzheimer’s disease, according to the complaint.

The complaint alleges that the defendants claimed training with Lumosity would 1) improve performance on everyday tasks, in school, at work, and in athletics; 2) delay age-related cognitive decline and protect against mild cognitive impairment, dementia, and Alzheimer’s disease; and 3) reduce cognitive impairment associated with health conditions, including stroke, traumatic brain injury, PTSD, ADHD, the side effects of chemotherapy, and Turner syndrome, and that scientific studies proved these benefits.

Unfortunately for consumers, Lumoisty did not have the science to back up its ads.

The proposed stipulated federal court order requires the company and the individual defendants, co-founder and former CEO Kunal Sarkar and co-founder and former Chief Scientific Officer Michael Scanlon, to have competent and reliable scientific evidence before making future claims about any benefits for real-world performance, age-related decline, or other health conditions.

The order also imposes a $50 million judgment against Lumos Labs, which will be suspended due to its financial condition after the company pays $2 million to the Commission. The order requires the company to notify subscribers who signed up for an auto-renewal plan between January 1, 2009 and December 31, 2014 about the FTC action and to provide a means to cancel their subscription

 


Carlisle E. said
415 days ago
I am outraged at this, Further, I have not been contacted by Lumosity to offer to cancel/refund my subscription(s).


sonia c. said
409 days ago
I have not been notified by Lumosity to offer to cancel/refund my subscription


d h. said
285 days ago
i also have not been contacted by them and i subscribed last September 2015


d h. said
285 days ago
i have not been notified since subscribing in sept 2015


John S. said
265 days ago
Same issue here. I think that Lumosity didn't do a full disclosure of all the people. I had/have a lifetime subscription within the complaint period and was not notified so they obviously didn't give all the names. Any recourse?

Submit a Response Are you having the same issue? Do you have a solution? Either way, chime in!

I would like to speak with a lawyer about my legal rights in this matter.

Same or similar issue but with a different company?

I would like to join the lawsuit.

Sign up for the Got a Class Action newsletter?

I have read and agree to the Terms and Conditions.

Contact A Lawyer Privately

  • This field is for validation purposes and should be left unchanged.